CDX
Daudi
Tumor indication
Lymphoid
Tumor subtype
Burkitt's Lymphoma
Description
DAUDI (Burkitt’s Lymphoma CDX Model)
The DAUDI cell line was derived from a patient with Burkitt’s lymphoma. It represents an Epstein–Barr virus (EBV)-positive B-cell lymphoma model. DAUDI has been a cornerstone for hematology research and drug development. Its growth characteristics make it useful in studying B-cell malignancies and targeted therapies.
Key Features:
- Derived from Burkitt’s lymphoma.
- EBV-positive B-cell line.
- Strong growth in suspension culture.
- Useful for lymphoma drug discovery.
Applications:
DAUDI supports studies of B-cell lymphoma biology and immunotherapy evaluation. It is frequently used to test cytotoxic agents and targeted therapies. Researchers employ it to study EBV-associated oncogenesis. Its reproducibility has made it a standard in hematologic oncology research.
Details
- Tumor indication
- Lymphoid
- Tumor subtype
- Burkitt's Lymphoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.